Ethics, error, and initial trials of efficacy

about

Ethics and epistemology of accurate prediction in clinical research.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review Controlling Brain Cells With Light: Ethical Considerations for Optogenetic Clinical Trials

P2860

Q30367094-DB56BAFA-9DC4-41CF-8744-5BF83BA4A871 Q36270115-A212B140-0B28-4917-92F9-6B766FD2EF65 Q58106799-980EF08A-A06B-41D0-AC7A-4C7D6CC92E4D

P2860

Ethics, error, and initial trials of efficacy

Item

http://www.wikidata.org/entity/Q42395017

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Ethics, error, and initial trials of efficacy

@en

Ethics, error, and initial trials of efficacy

@nl

type

Item

label

Ethics, error, and initial trials of efficacy

@en

Ethics, error, and initial trials of efficacy

@nl

prefLabel

Ethics, error, and initial trials of efficacy

@en

Ethics, error, and initial trials of efficacy

@nl

P1476

Ethics, error, and initial trials of efficacy

@en

P2093

Spencer Phillips Hey

http://www.w3.org/2001/XMLSchema#string

P2860

Can the pharmaceutical industry reduce attrition rates?

Optimism bias leads to inconclusive results-an empirical study.

Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.

Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or concepts

The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision.

Extending clinical equipoise to phase 1 trials involving patients: unresolved problems

Research ethics. Beyond access vs. protection in trials of innovative therapies.

Improving the design of phase II trials of cytostatic anticancer agents.

Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.

Design issues of randomized phase II trials and a proposal for phase II screening trials.

P304

184fs16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3005684

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

184

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan Kimmelman

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236666330

http://www.w3.org/2001/XMLSchema#string

P698

23658242

http://www.w3.org/2001/XMLSchema#string

P921

research ethics

P932

4516405

http://www.w3.org/2001/XMLSchema#string

Ethics, error, and initial trials of efficacy

about

P2860

P2860

Ethics, error, and initial trials of efficacy

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932